MX381639B - Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. - Google Patents

Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.

Info

Publication number
MX381639B
MX381639B MX2019007587A MX2019007587A MX381639B MX 381639 B MX381639 B MX 381639B MX 2019007587 A MX2019007587 A MX 2019007587A MX 2019007587 A MX2019007587 A MX 2019007587A MX 381639 B MX381639 B MX 381639B
Authority
MX
Mexico
Prior art keywords
treatment
dry eye
eye disease
ophthalmic composition
provides
Prior art date
Application number
MX2019007587A
Other languages
English (en)
Spanish (es)
Other versions
MX2019007587A (es
Inventor
Alice Meides
Bernhard Günther
Frank LÖSCHER
Hartmut Voss
Jörg Haisser
Markus Beier
Sonja Krösser
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of MX2019007587A publication Critical patent/MX2019007587A/es
Publication of MX381639B publication Critical patent/MX381639B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14Details; Accessories therefor
    • A61J1/1468Containers characterised by specific material properties
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06Ampoules or carpules
    • A61J1/067Flexible ampoules, the contents of which are expelled by squeezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019007587A 2016-12-23 2017-12-20 Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. MX381639B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16206735 2016-12-23
EP17165578 2017-04-07
PCT/EP2017/083770 WO2018115097A1 (en) 2016-12-23 2017-12-20 Ophthalmic composition for treatment of dry eye disease

Publications (2)

Publication Number Publication Date
MX2019007587A MX2019007587A (es) 2019-12-16
MX381639B true MX381639B (es) 2025-03-13

Family

ID=61002978

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007587A MX381639B (es) 2016-12-23 2017-12-20 Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.

Country Status (14)

Country Link
US (1) US20180360908A1 (enExample)
EP (3) EP3777830B1 (enExample)
JP (2) JP7032404B2 (enExample)
KR (1) KR102288022B1 (enExample)
CN (1) CN110267645A (enExample)
AU (1) AU2017384650B2 (enExample)
BR (1) BR112019012791A2 (enExample)
CA (1) CA3045743C (enExample)
DK (1) DK3399962T3 (enExample)
ES (2) ES2965883T3 (enExample)
MX (1) MX381639B (enExample)
PL (1) PL3399962T3 (enExample)
PT (1) PT3399962T (enExample)
WO (1) WO2018115097A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012023421B1 (pt) 2010-03-17 2021-09-14 Novaliq Gmbh Composição farmacêutica para tratamento de aumento de pressão intraocular
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
CA3142049C (en) 2012-09-12 2023-08-29 Novaliq Gmbh Semifluorinated alkane compositions
CA2997744C (en) 2012-09-12 2019-12-31 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
CA2918419C (en) 2013-07-23 2022-05-03 Novaliq Gmbh Stabilized antibody compositions
WO2017055454A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds and their compositions
DK3356313T3 (da) 2015-09-30 2020-07-20 Novaliq Gmbh 2-perfluorhexyloktan til oftalmisk indgivelse
JP2019520357A (ja) 2016-06-23 2019-07-18 ノバリック ゲーエムベーハー 局所投与方法
WO2018054932A1 (en) 2016-09-22 2018-03-29 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
CN109906085B (zh) 2016-09-23 2024-03-08 诺瓦利克有限责任公司 含有环孢素的眼用组合物
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
SG11202002640YA (en) 2017-09-27 2020-04-29 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
CA3091308A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2019206956A1 (en) 2018-04-27 2019-10-31 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
US12472162B2 (en) * 2018-07-24 2025-11-18 Carefusion 213, Llc Ready-to-use, terminally sterile packaging for surgical antiseptic and method of use
MY206642A (en) * 2018-10-12 2024-12-30 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
US20220226426A1 (en) * 2019-05-24 2022-07-21 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
AU2020340561A1 (en) * 2019-09-06 2022-03-31 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
EP3861857A1 (en) * 2020-02-07 2021-08-11 Novaliq GmbH Antiparasitic compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
WO2013126602A1 (en) * 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) * 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
CA2997744C (en) * 2012-09-12 2019-12-31 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
KR20150095684A (ko) * 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
CN106572941B (zh) * 2014-08-13 2020-06-23 佛罗里达大学研究基金会股份有限公司 从眼药水中去除防腐剂

Also Published As

Publication number Publication date
ES2965883T3 (es) 2024-04-17
US20230043641A1 (en) 2023-02-09
PT3399962T (pt) 2020-09-03
EP3777830A1 (en) 2021-02-17
PL3399962T3 (pl) 2021-02-08
EP3399962B1 (en) 2020-06-10
BR112019012791A2 (pt) 2019-12-03
AU2017384650A1 (en) 2019-07-04
MX2019007587A (es) 2019-12-16
AU2017384650B2 (en) 2021-02-18
CA3045743C (en) 2023-08-29
EP3777830B1 (en) 2023-11-29
EP3399962A1 (en) 2018-11-14
JP7032404B2 (ja) 2022-03-08
WO2018115097A9 (en) 2018-08-23
EP3777830C0 (en) 2023-11-29
JP2020502197A (ja) 2020-01-23
US20180360908A1 (en) 2018-12-20
DK3399962T3 (da) 2020-09-07
WO2018115097A1 (en) 2018-06-28
JP2022050514A (ja) 2022-03-30
CN110267645A (zh) 2019-09-20
ES2819005T3 (es) 2021-04-14
EP4374851A3 (en) 2024-08-21
EP4374851A2 (en) 2024-05-29
KR20190100283A (ko) 2019-08-28
KR102288022B1 (ko) 2021-08-10
CA3045743A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
MX381639B (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
MX2021009673A (es) Moduladores de ror-gamma.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
MY206642A (en) Ophthalmic composition for treatment of dry eye disease
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2017001301A1 (es) Composiciones oftálmicas estabilizadas de omega 3
BR112015017929A8 (pt) di-hidropirimidinonas bicíclicas substituídas, composição farmacêutica que os compreende e uso
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
CY1121933T1 (el) Υποκατεστημενες δικυκλικες διυδροπυριμιδινονες και χρηση αυτων ως αναστολεις δραστικοτητας ελαστασης ουδετεροφιλου
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
MX378230B (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cáncer.